Longer survival and fewer metastases by @entity7305 and tegafur in XXXX -induced murine @entity694 .

@entity5 @entity7305 @entity18399 @entity8708 @entity35 @entity694
The anticancer effects of @entity7305 , tegafur and their combination were experimentally compared in @entity35 on the @entity8708 ( @entity18399 )-induced @entity694 . DMH at 20 mg/kg of body weight was injected subcutaneously to Donryu @entity35 once a week for 24 weeks long. Nineteen weeks after the start of DMH administration, early @entity694 were induced and, 28 weeks after, they developed into advanced @entity5 with distant metastases. From 19 weeks after the start of DMH injection, subcutaneous administration of @entity7305 at the dose of 2 mg/kg, oral administration of tegafur at 90 mg/kg and their combination were given to the @entity35 daily for nine weeks. The animals were sacrificed 28 weeks after the start of DMH administration. Tegafur was effective, but @entity7305 with or without tegafur was not effective against @entity5 . From 28 weeks after the start of DMH injection, @entity7305 , tegafur and their combination were administered to the @entity35 daily for four weeks. All of the @entity35 were necropsied when they died. The survival rate and mean survival days were significantly higher and longer in the @entity7305 groups than in the control @entity35 (p less than 0.05). The incidence of distant metastases was also significantly lower in the @entity7305 groups than in the control group.
